Agios Pharmaceuticals (AGIO) Non-Current Assets (2012 - 2026)

Agios Pharmaceuticals' Non-Current Assets history runs 15 years deep, the most recent figure standing at $350.1 million for Q1 2026.

• Quarterly Non-Current Assets fell 40.34% year-over-year to $350.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 29.55% YoY) and the FY2025 annual result came in at $355.2 million, down 49.09% from the prior year.
• Non-Current Assets was $350.1 million for Q1 2026 at Agios Pharmaceuticals, down from $355.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $717.6 million in Q3 2024 and bottomed at $103.3 million in Q4 2023.
• A 5-year average of $381.0 million and a median of $359.6 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets slumped 74.56% — and 2024, when it soared 575.42%.
• Agios Pharmaceuticals' Non-Current Assets stood at $405.9 million in 2022, then sank by 74.56% to $103.3 million in 2023, then surged by 575.42% to $697.6 million in 2024, then tumbled by 49.09% to $355.2 million in 2025, then fell by 1.42% to $350.1 million in 2026.
• Business Quant data shows AGIO's Non-Current Assets at $350.1 million in Q1 2026, $355.2 million in Q4 2025, and $352.6 million in Q3 2025.